Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 1, 2001, Pages 217-222

  Bermudez, L E ^a   Inderlied, C B ^a   Kolonoski, P ^a   Petrofsky, M ^a   Aralar, P ^a   Wu, M ^a   Young, L S ^a  

^a Kuzell Institute for Arthritis and Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; ETHAMBUTOL; MOXIFLOXACIN; RIFABUTIN;

ARTICLE; BACTERIOSTASIS; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; AZITHROMYCIN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; FLUOROQUINOLONES; MACROPHAGES; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; QUINOLINES; RIFABUTIN;

EID: 0035171461     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.1.217-222.2001     Document Type: Article

References (24)

1. Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice
2. Activities of BAY Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice
3. Mefloquine is active in vitro and in vivo against Mycobacterium avium complex
4. Activity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection
5. Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy
6. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS
7. Pulmonary infection with nontuberculous mycobacteria
8. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone
9. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man
10. Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome
11. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome
12. The Mycobacterium avium complex
13. Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods
14. Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex
15. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis
16. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model
17. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis
18. In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis
19. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis
20. Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells
21. Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages
22. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: A comparison in humans and other mammalian species
23. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: Tissue distribution in male rats
24. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects